Skip to main content
. 2020 May 19;22(5):e16629. doi: 10.2196/16629

Table 1.

Patients characteristics at baseline.

Variablesa Intervention group (n=79) Usual care group (n=56) P value
Index of multiple deprivation, n (%) N/Ab

20-30(most deprived) 9 (11.4) 6 (10.7)

30-40 46 (58.3) 31 (55.3)

40-50 0 (0) 0 (0)

50-60 6 (7.6) 4 (7.2)

60-70 6 (7.6) 8 (14.3)

70-80 (least deprived) 12 (15.1) 7 (12.5)
Age (years), n (%) .37

18-29 0 (0) 1 (1.8)

30-39 4 (5.1) 0 (0)

40-49 5 (6.3) 3 (5.4)

50-59 15 (19) 13 (23.2)

60-69 27 (34.2) 15 (26.8)

70-79 26 (32.9) 20 (35.7)

80+ 2 (2.5) 4 (7.1)
Gender, n (%) .90

Male 40 (50.7) 33 (59)

Female 39 (49.3) 23 (41)
Employment, n (%) .47

Full-time 22 (27.8) 10 (17.8)

Part-time 12 (15.2) 3 (5.4)

Unemployed 1 (1.2) 1 (1.8)

Unable to work due to disease 3 (3.8) 7 (12.5)

Retired 41 (52) 35 (62.5)
Number of pills prescribed to take per day, self-reported, mean (SD) 8.13 (6.21) 5.95 (5.14) .03
Number of different pills prescribed to take per day, self-reported, mean (SD) 5.74 (3.67) 4.57 (3.52) .06
Health condition, n (%) N/A

Hypertension 42 (53.2) 38 (67.9)

Type 2 diabetes 32 (40.5) 16 (28.6)

Comorbidities of hypertension, type 2 diabetes, and cholesterol 5 (6.3) 2 (3.5)
Medication adherence, mean (SD)

Number of days of adherence, last week 6.46 (1.23) 6.38 (1.29) .73

Percentage of adherence, last month 91.19 (13.11) 93.98 (33.32) .49

Medication Adherence Rating Scale 22.78 (2.81) 23.25 (2.32) .30

Repeat prescription 0.97 (0.20) 0.95 (0.26) .64
Quality of life, mean (SD)

EQ-5Dc, 5-items 1.71 (0.76) 1.74 (0.75) .86

EQ-5D, total health 76.01 (19.68) 47.83 (21.56) .74

aData are reported as means (SD) or number (percentage). Health condition: main comorbidities were extracted from prescription data. Index of Multiple Deprivation was calculated based on general practice postcode; 10: low Index of Multiple Deprivation to 100: high Index of Multiple Deprivation. Repeat prescription was defined and calculated: supply of medication claimed by the patients, excluding the next prescription day the medication was claimed, and divided by the number of days of assessment period. Assessment period at baseline refers to the supply claimed by each patient before the start of the study (ie, consent process). Assessment period at follow-up refers to the last 2 months of the study. Ratio was calculated per patient due to different denominators (eg, supply prescribed to be issued every 28 or 56 days). The overall adherence value was calculated by averaging each patient’s ratio and dividing by the total number of patients.

bN/A: not applicable.

cEQ-5D-5L: descriptive system of health-related quality of life states consisting of five dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The response record five levels of severity (no problems/slight problems/moderate problems/ severe problems/ extreme problems) within a particular EQ-5D dimension.